investorscraft@gmail.com

Intrinsic Value of Clarus Therapeutics Holdings, Inc. (CRXT)

Previous Close$0.00
Intrinsic Value
Upside potential
Previous Close
$0.00
* Our model cannot be used “out of the box” for the valuation of this stock. You can still do your own valuation by changing the valuation input parameters.

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-06-30.

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %119.1NaN
Revenue, $14NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m54NaN
Operating income, $m-40NaN
EBITDA, $m-40NaN
Interest expense (income), $mNaN
Earnings before tax, $m-39NaN
Tax expense, $m2NaN
Net income, $m-41NaN

BALANCE SHEET

Cash and short-term investments, $m26NaN
Total assets, $m52NaN
Adjusted assets (=assets-cash), $m25NaN
Average production assets, $m10NaN
Working capital, $m-14NaN
Total debt, $m42NaN
Total liabilities, $m68NaN
Total equity, $m-16NaN
Debt-to-equity ratio-2.655NaN
Adjusted equity ratio-0.003NaN

CASH FLOW

Net income, $m-41NaN
Depreciation, amort., depletion, $m0NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-44NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-0NaN
Free cash flow, $m-44NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m-14
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount